MedTrace Logo

Macromolecular Imaging of White and Gray Matter Pathology in Multiple Sclerosis

NCT04415372 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2026-04-28

No results posted yet for this study

Summary

The overall purpose of this research is to determine whether new macromolecular measures optimized for whole brain (gray matter and white matter) magnetic resonance imaging (MRI), predict neuro-cognitive impairment in multiple sclerosis (MS) patients.

Conditions

Interventions

DIAGNOSTIC_TEST

MRI

The MRI protocol will include conventional testing for MS lesion detection and functional MR imaging to localize associated neurocognitive domains in each subject.

DIAGNOSTIC_TEST

Neuropsychological Testing

A comprehensive battery of neuropsychological tests will be administered to assess memory, new learning, spatial processing and higher executive function.

Sponsors & Collaborators

  • National Institute for Biomedical Imaging and Bioengineering (NIBIB)

    collaborator NIH

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Alexey Samsonov, PhD · UW Madison

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-19
Primary Completion
2027-04-30
Completion
2027-04-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04415372 on ClinicalTrials.gov